Gradalis, Inc. | MedPath

Robust Pipeline for Ewing Sarcoma Treatment: 25+ Companies Advancing Novel Therapies

3 months ago

• A comprehensive pipeline analysis reveals over 25 pharmaceutical companies actively developing treatments for Ewing Sarcoma, with multiple promising candidates in various clinical stages. • Gradalis's Vigil, a personalized cancer immunotherapy, has advanced to Phase III trials in combination with irinotecan and temozolomide for Ewing Sarcoma treatment. • Key emerging therapies include Oncternal's ONCT216, a first-in-class ETS-family transcription factor inhibitor, and Salarius's SP-2577, currently in Phase I/II trials for multiple sarcoma types.

FDA Grants RMAT Designation to Gradalis' Personalized Immunotherapy for Advanced Ovarian Cancer

4 months ago

• Gemogenovatucel-T (Vigil) received FDA RMAT designation for treating advanced ovarian cancer patients with specific genetic profiles, based on significant survival improvements in clinical trials. • The phase 2b VITAL trial demonstrated positive trends in recurrence-free survival and statistically significant improvements in overall survival for BRCAwt patients. • The personalized immunotherapy works by targeting clonal neoantigens and modulating immune response through bi-shRNA technology, showing promise as a safer and more precise treatment option.